StockData
Rapid Micro Biosystems, Inc. logo

Rapid Micro Biosystems, Inc. (RPID) stock

RPIDNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 7/3057% below fair value
$0.65−0.02 (-2.98%)

Close on Nov 13, 2026Market cap $32.65MP/E –Yield –

Earnings

Rapid Micro Biosystems's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 6, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$8.10M
+11.0% on a year earlier
EPS, Q2 FY2026
-$0.27
-$0.27 a year earlier
Latest guidance
Lowered
Aug 7, 2026 · 4 items

Quarterly results

Revenue and earnings per share from each of Rapid Micro Biosystems's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 6, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 7, 2026before the open$8.10M+11.0%-$0.27Release
Q1 FY2026ended Mar 31, 2026May 13, 2026during market hours$8.00M+11.1%-$0.31Release
Q4 FY2025ended Dec 31, 2025Mar 12, 2026before the open$11.30M+37.8%-$0.28Release
Q3 FY2025ended Sep 30, 2025Nov 7, 2025before the open$7.80M+2.6%-$0.26Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025before the open$7.30M+10.6%-$0.27Release
Q1 FY2025ended Mar 31, 2025May 9, 2025before the open$7.20M+28.6%-$0.26Release
Q4 FY2024ended Dec 31, 2024Feb 28, 2025before the open$8.20M+30.2%-$0.22Release
Q3 FY2024ended Sep 30, 2024Nov 1, 2024before the open$7.60M+24.6%-$0.26Release
Q2 FY2024ended Jun 30, 2024Aug 2, 2024before the open$6.60M+32.0%-$0.29Release
Q1 FY2024ended Mar 31, 2024May 3, 2024before the open$5.60M+12.0%-$0.31Release
Q4 FY2023ended Dec 31, 2023Mar 1, 2024before the open$6.30M+43.2%-$0.26Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Rapid Micro Biosystems's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
total revenueFY2026$37.00M – $41.00M$37.00M – $41.00MReaffirmedAug 7, 2026
total revenueFY2026$37.00M – $41.00M–NewMar 12, 2026
gross marginsFY202620%–NewMar 12, 2026
total gross margin percentageFY202620%20%ReaffirmedAug 7, 2026
Growth Direct system placementsFY202630 – 3830 – 38ReaffirmedAug 7, 2026
Growth Direct system placementsFY202630 – 38–NewMar 12, 2026
system validationFY202627–LoweredAug 7, 2026

Guidance vs results

The last range Rapid Micro Biosystems gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$33.00M$33.60MΣ4QAbove range

Guidance history

Every forecast Rapid Micro Biosystems put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 7, 2026total gross margin percentageFY202620%Reaffirmed
Aug 7, 2026Growth Direct system placementsFY202630 – 38Reaffirmed
Aug 7, 2026system validationFY202627Lowered
Aug 7, 2026total revenueFY2026$37.00M – $41.00MReaffirmed
May 13, 2026gross margin percentageFY202620%New
May 13, 2026Growth Direct system placementsFY202630 – 38New
May 13, 2026total revenue guidance rangeFY2026$37.00M – $41.00MNew
Mar 12, 2026gross marginsFY202620%New
Mar 12, 2026Growth Direct system placementsFY202630 – 38New
Mar 12, 2026total revenueFY2026$37.00M – $41.00MNew
Nov 7, 2025Growth Direct system placementsFY202527New
Nov 7, 2025total revenue guidanceFY2025$33.00MNew
Aug 12, 2025total revenueFY2025$32.00MReaffirmed
May 9, 2025system placementsFY202521 – 25Reaffirmed
May 9, 2025total revenueFY2025$32.00MReaffirmed
Feb 28, 2025system placementsFY202521 – 25New
Feb 28, 2025total revenueFY2025$32.00MNew
Nov 1, 2024placement of systemsFY202420Reaffirmed
Nov 1, 2024growthFY2024+20%New
Nov 1, 2024total revenueFY2024$27.00MReaffirmed

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Rapid Micro Biosystems filed with the SEC as exhibits to Form 8-K or 6-K

  1. Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results
    Results
  2. Rapid Micro Biosystems Reports First Quarter 2026 Financial Results
    Results
  3. Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
    Results
  4. Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct ® Platform
    Results
  5. Rapid Micro Biosystems Announces Record Preliminary Unaudited
    Results
  6. Rapid Micro Biosystems Reports Third Quarter 2025 Financial Results; Announces Record Multi-System Customer Order and Raises Full-Year Revenue and System Placement Guidance
    Results
  7. Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results
    Results
  8. Rapid Micro Biosystems Enters into Five-Year, $45 Million Term Loan Facility with Trinity Capital Inc.
    Results
  9. Dear RMB Team Members and Shareholders:
    News
  10. Rapid Micro Biosystems Reports First Quarter 2025 Financial Results
    Results
  11. 8-K exhibit EX-99.1
    Update
  12. Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Guidance
    Results
  13. Rapid Micro Biosystems Announces Global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany
    Update
  14. 8-K exhibit EX-99.1
    Update
  15. Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and
    Results

See a number that looks wrong?